Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma
- 1 March 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Acta Endocrinologica
- Vol. 166 (3), 451-458
- https://doi.org/10.1530/eje-11-0918
Abstract
Background: There is a strong rationale in the use of antiangiogenic therapy in the management of adrenocortical carcinoma (ACC). Metronomic administration of chemotherapy and antiangiogenic drugs can be synergistic in targeting endothelial cells.Objective: We assessed the activity of sorafenib plus metronomic paclitaxel as second/third-line therapy in advanced ACC patients. We also tested the activity of sorafenib and paclitaxel against NCI-H295R in vitro.Design: Multicenter, prospective phase II trial.Setting: Referral centers for ACC.Methods: Twenty-five consecutive metastatic ACC patients who progressed after mitotane plus one or two chemotherapy lines were planned to be enrolled. The patients received a combination of i.v. paclitaxel (60 mg/m2 every week) and oral sorafenib (400 mg twice a day) till progression. The primary aim was to measure the progression-free survival rate after 4 months and the secondary aims were to assess the objective response rate and toxicity.Results: Tumor progression was observed in nine evaluable patients at the first assessment. These results led to the premature interruption of the trial. The treatment was well tolerated. The most relevant toxicities were fatigue, being grade 2 or 3 in four patients, and hypophosphatemia, being grade 3 in three patients. In the in vitro study, sorafenib impaired the viability of H295R cells with dose–response and time–response relationships. The in vitro sorafenib activity was not increased in combination with paclitaxel.Conclusions: Despite the in vitro activity, sorafenib plus weekly paclitaxel is an inactive salvage treatment in patients with advanced ACC and should not be recommended.Keywords
This publication has 25 references indexed in Scilit:
- Metronomic Chemotherapy: Principles and Lessons Learned from Applications in the Treatment of Metastatic Prostate CancerPublished by Springer Science and Business Media LLC ,2009
- Emerging drugs for adrenocortical carcinomaEmerging Drugs, 2008
- Prognostic Parameters of Metastatic Adrenocortical CarcinomaJournal of Clinical Endocrinology & Metabolism, 2007
- Adrenocortical Carcinoma: Clinical UpdateJournal of Clinical Endocrinology & Metabolism, 2006
- Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 WeeksJournal of Clinical Oncology, 2005
- A Comparative Analysis of Low-Dose Metronomic Cyclophosphamide Reveals Absent or Low-Grade Toxicity on Tissues Highly Sensitive to the Toxic Effects of Maximum Tolerated Dose RegimensCancer Research, 2004
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- Paclitaxel Is an Effective Antiproliferative Agent on the Human NCI-H295 Adrenocortical Carcinoma Cell LineChemotherapy, 1998
- PaclitaxelDrugs & Aging, 1998
- The Italian registry for adrenal cortical carcinoma: Analysis of a multiinstitutional series of 129 patientsSurgery, 1996